clinical trial · NCT06087835
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
Chronic Kidney Disease With High ProteinuriaZibotentan/DapagliflozinDapagliflozin
brief summary
This is a Phase III, randomised, multicentre, double-blinded study to evaluate efficacy, safety and tolerability of treatment with zibotentan/dapagliflozin and dapagliflozin alone in participants with chronic kidney disease (CKD) and high proteinuria
started
Nov 7, 2023
primary completion
Feb 18, 2027
completion
Feb 18, 2027
last updated
May 15, 2026
official title
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin Alone in Participants With Chronic Kidney Disease and High Proteinuria
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol